Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

• Status: Recruiting
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Collaborator: Beijing Bethune public welfare fund

Criteria

Inclusion Criteria:

• age >= 18 years old

• competent in signing the informed consent

• no severe systemic diseases unrelated to uveitis

• fulfill the criteria of refractory UME

Exclusion Criteria:

• pregnant or preparing pregnancy

• already in other clinical trials

• blood pressure >= 180/110mmHg

• BCVA of the contralateral eye <= 20/200

• cardiovascular events within 3 months